GlaxoSmithKline
GSK
$35.99
Share price
1.41%
Change (1 day)
4.05%
Change (1 year)
Categories
GlaxoSmithKline (GSK) - Total debt
Total debt on the balance sheet as of September 2023 : $25.40 B
According to GlaxoSmithKline's latest financial reports the company's total debt is $25.40 B. A company’s total debt is the sum of all current and non-current debts.
GlaxoSmithKline - Total debt on balance sheet (from 2001 to 2023)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2022-12-31 | $25.43 B | -22.04% |
| 2021-12-31 | $32.62 B | -11.83% |
| 2020-12-31 | $37.00 B | -7.49% |
| 2019-12-31 | $40.00 B | 20.92% |
| 2018-12-31 | $33.08 B | 43.24% |
| 2017-12-31 | $23.09 B | -0.46% |
| 2016-12-31 | $23.20 B | -5.86% |
| 2015-12-31 | $24.64 B | -15.72% |
| 2014-12-31 | $29.24 B | -2.83% |
| 2013-12-31 | $30.09 B | 1.74% |
| 2012-12-31 | $29.58 B | 27.98% |
| 2011-12-31 | $23.11 B | -0.84% |
| 2010-12-31 | $23.31 B | -11.39% |
| 2009-12-31 | $26.30 B | 10.89% |
| 2008-12-31 | $23.72 B | 12.97% |
| 2007-12-31 | $21.00 B | 94.75% |
| 2006-12-31 | $10.78 B | -3.07% |
| 2005-12-31 | $11.12 B | -2.82% |
| 2004-12-31 | $11.44 B | 25.41% |
| 2003-12-31 | $9.12 B | 55.81% |
| 2002-12-31 | $5.85 B | 9.46% |
| 2001-12-31 | $5.35 B |
Total debt for similar companies or competitors
| Company | Total debt | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | $25.18 B | -0.85% | 🇨🇭 Switzerland |
 Pfizer PFE | $65.34 B | 157.19% | 🇺🇸 USA |
 Sanofi SNY | $22.85 B | -10.05% | 🇫🇷 France |
 Merck MRK | $36.91 B | 45.29% | 🇺🇸 USA |
 AstraZeneca AZN | $28.57 B | 12.48% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | $20.29 B | -20.10% | 🇮🇱 Israel |
 Dynavax Technologies
DVAX | $0.25 B | -98.99% | 🇺🇸 USA |